Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Source: View publication →
The CLEAR trial demonstrated that the combination of lenvatinib and pembrolizumab significantly improved progression-free survival, overall survival, and objective response rates compared to sunitinib as a first-line treatment for advanced clear-cell renal cell carcinoma.
Key Findings
Study Design
Study Limitations
Clinical Significance
The CLEAR trial results established lenvatinib plus pembrolizumab as a robust first-line standard-of-care option for patients with advanced renal cell carcinoma, offering superior clinical efficacy across all IMDC risk groups compared to the historical standard, sunitinib.
Historical Context
For many years, sunitinib was the gold-standard first-line therapy for metastatic renal cell carcinoma. The CLEAR trial represents a major shift toward combination regimens involving immune checkpoint inhibitors and tyrosine kinase inhibitors, aiming to improve durable response rates and survival in this patient population.
Guided Discussion
High-yield insights from every perspective
The CLEAR trial utilized Lenvatinib, a multi-kinase inhibitor, alongside Pembrolizumab. What is the physiological rationale for combining VEGF-targeted therapy with PD-1 inhibition in renal cell carcinoma?
Key Response
Clear-cell RCC is characterized by VHL gene mutations leading to VEGF overexpression. VEGF not only promotes angiogenesis but also induces an immunosuppressive tumor microenvironment by inhibiting dendritic cell maturation and increasing MDSCs and Tregs. Combining a VEGFR-TKI like Lenvatinib with a PD-1 inhibitor like Pembrolizumab creates a synergistic effect: the TKI 'normalizes' the vasculature and reduces immunosuppression, allowing Pembrolizumab-activated T-cells to more effectively infiltrate and attack the tumor.
A patient with metastatic RCC starts the CLEAR regimen (Lenvatinib 20mg daily + Pembrolizumab 200mg Q3W). Given the trial's safety data, how should you counsel the patient regarding the likelihood and management of dose modifications?
Key Response
In the CLEAR trial, 82.4% of patients in the Lenvatinib-Pembrolizumab arm experienced Grade 3 or higher adverse events, and a significant majority required dose reductions or interruptions of Lenvatinib (median dose was roughly 14mg/day despite the 20mg starting dose). Residents must know that starting at 20mg is necessary to achieve the reported 23.9-month PFS, but proactive dose titration for hypertension, diarrhea, and fatigue is the standard of care to maintain treatment persistence.
The CLEAR trial reported an objective response rate (ORR) of 71% and a complete response (CR) rate of 16.1% for Lenvatinib plus Pembrolizumab. How do these metrics influence your choice between this regimen and Ipilimumab/Nivolumab for a patient with high-volume, symptomatic intermediate-risk disease?
Key Response
For symptomatic, high-volume disease, the high ORR (71%) and rapid onset of response with IO-TKI (Len/Pem) are often preferable to ensure quick cytoreduction and symptom control. While IO-IO (Ipi/Nivo) offers potential for long-term treatment-free survival in some patients, the CR rate of 16.1% in CLEAR is the highest reported among the major IO-TKI trials (e.g., CheckMate 9ER or KEYNOTE-426), making Len/Pem a potent option for achieving deep responses.
The PFS of 23.9 months in the Len/Pem arm of the CLEAR trial is the longest reported to date in a Phase III trial for advanced RCC. Does this unprecedented PFS justify the use of Len/Pem as the preferred first-line agent despite the potentially higher toxicity compared to Axitinib/Pembrolizumab?
Key Response
This is a practice-defining trade-off. While Axitinib/Pembrolizumab is often perceived as more 'manageable' due to Axitinib's short half-life, the nearly 2-year median PFS of Len/Pem is clinically superior to the ~15 months seen in KEYNOTE-426. For fit patients, the attending's role is to leverage the superior efficacy of Len/Pem while utilizing expert side-effect management, as the OS benefit (HR 0.66) and PFS benefit are robust across all IMDC risk groups.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The CLEAR trial used a three-arm design comparing Len/Pem and Len/Everolimus against Sunitinib. Critically evaluate the implications of the Lenvatinib-Everolimus arm results on our understanding of the relative contributions of PD-1 vs. mTOR inhibition when paired with a potent TKI.
Key Response
The Lenvatinib-Everolimus arm showed a significant PFS benefit over Sunitinib (14.7 vs 9.2 months) but failed to show a significant Overall Survival (OS) benefit (HR 1.15; 95% CI, 0.88-1.50) at the primary analysis. This suggests that while dual pathway inhibition (VEGF/mTOR) can delay progression, the immune-modulatory component of the PD-1 inhibitor is likely essential for converting those responses into a survival advantage, highlighting the unique role of immunotherapy in achieving durable clinical benefit in RCC.
As a reviewer, how would you address the potential for informative censoring and the choice of Sunitinib as a control arm in a 2021 publication when the landscape had already shifted toward IO-based doublets?
Key Response
A critical reviewer would flag that while Sunitinib was the standard when the trial launched, its relevance as a control diminished by the time of publication. Furthermore, with high toxicity-related discontinuation rates (37.2% for Len/Pem), one must scrutinize whether PFS results were biased by how patient dropouts were handled in the statistical model. If patients who discontinued due to toxicity were censored early, it could theoretically inflate the PFS estimates compared to real-world outcomes where patients might switch to less effective subsequent lines.
Based on the CLEAR data, how should the strength of recommendation for Lenvatinib-Pembrolizumab be categorized for 'Favorable Risk' patients compared to the current NCCN/EAU standards?
Key Response
Current NCCN guidelines list Len/Pem as a Category 1 'Preferred' option for all risk groups, including favorable risk. This is supported by the CLEAR trial subgroup analysis showing a PFS HR of 0.47 for favorable-risk patients. While Ipi/Nivo is not recommended for favorable risk due to lack of superiority over Sunitinib in that subgroup, Len/Pem's ability to outperform Sunitinib regardless of IMDC status makes it a primary choice for updating guidelines to prioritize IO-TKI combinations in the favorable-risk setting.
Clinical Landscape
Noteworthy Related Trials
METEOR Trial
Tested
Cabozantinib
Population
Advanced renal cell carcinoma previously treated with anti-VEGFR therapy
Comparator
Everolimus
Endpoint
Progression-free survival
CheckMate 214 Trial
Tested
Nivolumab plus Ipilimumab
Population
Advanced renal cell carcinoma
Comparator
Sunitinib
Endpoint
Overall survival, objective response rate, and progression-free survival
KEYNOTE-426 Trial
Tested
Pembrolizumab plus Axitinib
Population
Advanced renal cell carcinoma
Comparator
Sunitinib
Endpoint
Overall survival and progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis